Navigation Links
Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product
Date:7/21/2008

SEATTLE, July 21 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has received an R&D contract award from the ONR for approximately $1.6 million to optimize its lead drug candidate for hearing regeneration. SPI has developed a proprietary technology for regenerating auditory sensory cells within the inner ear of mammals involving p27Kip1, a cyclin dependent kinase inhibitor or CKI. CKIs shut down cell division or proliferation in many developing cells and tissues and are often expressed in adult organs to maintain cellular quiescence or terminal differentiation. In the hearing organ of mammals (cochlea), p27Kip1 prevents cellular proliferation and regeneration. For this reason, sensorineural hearing loss is irreversible and often progressive. Once auditory hair cells are lost they are never replaced. In p27 knockout mice, auditory hair cell regeneration occurs due to the unique ability of supporting cells to re-enter the cell cycle, proliferate and regenerate in to supporting cells and replacement hair cells. In p27 wild type mice, this proliferative and regenerative ability is absent. SPI has developed this novel technology into a drug that inhibits p27Kip1 in wild type cells and tissues, and is injecting that drug into the cochlea of deafened Guinea pigs. Results indicate that renewed supporting cell proliferation and hair cell regeneration occur in animals that have lost their hearing due to ototoxic or acoustic injury. In some animals, a return of auditory function has been observed. The ultimate goal of this work is to restore hearing to the severe to profoundly hearing impaired or deaf, especially those with recent traumatic injuries. This novel regenerating strategy may be applied to other non regenerating systems such as the brain or retina where p27Kip1 plays a similar role.

In 2005, the Office of Naval Research began funding this hearing regeneration project. This new funding brings the total level of funding on this specific p27 project to approximately $3 million.

Sound Pharmaceuticals, Inc. is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please contact Jonathan Kil, MD, President and CEO, 206-634-2559 or visit http://www.soundpharma.com.


'/>"/>
SOURCE Sound Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Heel Ultrasound Helps Detect Fracture Risk
2. Accuracy of ultrasound screening in pregnancy: Effects of examiner and device quality unclear
3. Simple ultrasound exam may predict osteoporosis risk
4. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
5. New Heart Ultrasound Research Shows Hope for Diagnosing and Treating Fatal Heart Conditions
6. Siemens New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography
7. Mindrays DC-3 Color Ultrasound Gains U.S. FDA 510(k) Clearance
8. Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES!
9. World No Tobacco Day Sounds Urgent Call for Nations to Fight Tobacco Use, Save Lives
10. ALOKA to Unveil a New Compact ProSound Diagnostic Ultrasound System
11. Journal of Ultrasound In Medicine features bioeffects consensus report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards ... full spectrum of disordered eating, announced today that the 2017 Symposium set a new ... and several countries converged on the Green Valley Resort in Las Vegas. , ...
(Date:3/24/2017)... Northridge, CA (PRWEB) , ... March 24, 2017 ... ... Dr. Ramin Assili, announce that they are now offering treatments for sleep apnea ... treated at dental offices. Sleep apnea , specifically the obstructive type, is ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower ... upgrading their training and leads programs. , In February, 2017, Empower Brokerage introduced ... agents, Performance Partners is designed to teach how to maximize their sales efforts, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... Virginia (PRWEB) , ... March 23, 2017 , ... ... public health services to their communities, 16 more public health departments have been ... week’s decisions bring another 4.5 million people into the expanding network of communities ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% ... the highest revenue, and is projected to dominate the market during the study period. ... ... Market Research Logo ...
(Date:3/24/2017)... 24, 2017  Zymo Research Corp., also ... Robotics, Inc., who designs, manufactures and distributes ... that teams Zymo Research,s DNA methylation detection ... extraction products with Hamilton,s high-throughput automation platforms. ... for microbiomics and RNA isolation for use ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
Breaking Medicine Technology: